TNF antagonist better in treatment of early rheumatoid arthritis
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trialLancet. 2009 Aug 8;374(9688):459-66.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
258 patients with early stage rheumatoid arthritis, who were unresponsive to 4 months treatment with methotrexate, were randomized to receive additional treatment with Infliximab (tumor necrosis factor antagonist) or sulfasalazine and hydroxychloroquine. This trial assessed the efficacy of the use of tumor necrosis factor antagonists in treatment of rheumatoid arthritis, while comparing this treat...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE